Joseph Tucker

Boston, Massachusetts, USA

SUMMARY OF QUALIFICATIONS
· Two decades experience including CEO, Exec. Chairman roles in NASDAQ & TSX microcap biotech companies
· Strong track record with $80M in equity raises, one IPO, one go-public merger, and three acquisition exits

Enveric Biosciences narrows net loss, advances lead drug candidate
Enveric Biosciences Inc. (NASDAQ: ENVB) reported its financial results for the third quarter of 2024 and provided a corporate update yesterday. Enveric said it made...
Enveric Biosciences narrows net loss, advances lead drug candidate Article
Nov 15, 2024
Enveric inks $62M licensing deal for psilocin prodrug
Enveric Biosciences (NASDAQ: ENVB) agreed to license one of its experimental psychedelic drug candidates to MycoMedica Life Sciences in a deal worth as much as...
Enveric inks $62M licensing deal for psilocin prodrug Article
Nov 12, 2024
Enveric Biosciences narrows second-quarter loss, pushes non-hallucinogenic pipeline
Enveric Biosciences (NASDAQ: ENVB) reported a narrower second-quarter loss for the second quarter, which ended June 30, but it might need more funding to keep...
Enveric Biosciences narrows second-quarter loss, pushes non-hallucinogenic pipeline Article
Aug 13, 2024
Another Psychedelic Drug Derivative Secures Patent and Awaits FDA Approval
Everyone is watching MAPS and Lykos Therapeutics to see whether the FDA will approve MDMA-assisted therapy for PTSD, and if Lykos will secure a patent...
Another Psychedelic Drug Derivative Secures Patent and Awaits FDA Approval Article
Jul 30, 2024
Enveric Biosciences nabs patent for “next-gen” psilocin prodrug
Enveric Biosciences (NASDAQ: ENVB) has received a U.S. patent for its drug candidate EB-002, the company announced Wednesday. The patent (No. 11,945,778) covers methods of...
Enveric Biosciences nabs patent for “next-gen” psilocin prodrug Article
Jul 11, 2024
Enveric Biosciences Loses $6.4 Million in Q2, Announces Cost-Reduction Plan
Florida-based Enveric Biosciences Inc. (Nasdaq: ENVB) continued to bleed cash in its second quarter of 2023 with a $6.4 million loss, while making progress toward...
Enveric Biosciences Loses $6.4 Million in Q2, Announces Cost-Reduction Plan Article
Aug 14, 2023
Joseph Tucker, CEO of Enveric Biosciences, Sits in the Investor Hotseat on December 8th
During this edition of the Investor Hotseat, host Dustin Robinson of Iter Investments is joined by Dr. Joseph Tucker of Enveric Biosciences. Enveric Biosciences is...
Joseph Tucker, CEO of Enveric Biosciences, Sits in the Investor Hotseat on December 8th Article
Dec 05, 2022

Last updated: Dec 05, 2022
Request Deletion